IL1B and hyperlipidemia: Moreover, orally active trans-PAO did not reduce or induce hyperlipidemia-induced IL-1β levels in the plaques or in the serum of Apoe−/− mice, which was consistent with our observations on trans-PAO's impact on IL-1β secretion in macrophages.